Amgen (AMGN)
(Delayed Data from NSDQ)
$333.99 USD
-1.54 (-0.46%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $332.50 -1.49 (-0.45%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Amgen (AMGN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Downside to Average Price Target |
---|---|---|---|
$316.86 | $380.00 | $170.00 | -5.56% |
Price Target
Based on short-term price targets offered by 22 analysts, the average price target for Amgen comes to $316.86. The forecasts range from a low of $170.00 to a high of $380.00. The average price target represents a decline of 5.56% from the last closing price of $335.53.
Analyst Price Targets (22)
Broker Rating
Amgen currently has an average brokerage recommendation (ABR) of 2.12 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 26 brokerage firms. The current ABR compares to an ABR of 2.12 a month ago based on 26 recommendations.
Of the 26 recommendations deriving the current ABR, 13 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 50% and 3.85% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 3.85%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 13 | 13 | 13 | 13 | 13 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 10 | 10 | 10 | 10 | 10 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.12 | 2.12 | 2.12 | 2.12 | 2.12 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/24/2024 | Cowen & Co. | Yaron Werber | Strong Buy | Strong Buy |
6/27/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
6/27/2024 | Argus Research Corp. | David A Toung | Strong Buy | Strong Buy |
5/21/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
5/20/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/13/2024 | Atlantic Equities | Steven K Chesney | Strong Sell | Strong Sell |
5/9/2024 | Mizuho SecuritiesUSA | Salim Syed | Hold | Hold |
5/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/3/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
5/3/2024 | William Blair | Matt Phipps | Hold | Strong Buy |
5/3/2024 | Not Identified | Not Identified | Strong Sell | Hold |
5/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/17/2024 | UBS | Colin N Bristow | Hold | Hold |
4/3/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
3/28/2024 | Raymond James | Gary Nachman | Hold | Hold |
3/7/2024 | Not Identified | Not Identified | Hold | Hold |
2/7/2024 | Goldman Sachs | Salveen Richter | Not Available | Strong Buy |
2/7/2024 | SVB Securities | David Risinger | Strong Buy | Hold |
2/7/2024 | Robert W. Baird & Co. | Brian P Skorney | Strong Sell | Strong Sell |
12/21/2023 | Daiwa America | Narumi Nakagiri | Not Available | Strong Buy |
12/7/2023 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
9/27/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.12 |
ABR (Last week) | 2.12 |
# of Recs in ABR | 26 |
Average Target Price | $316.86 |
LT Growth Rate | 6.20% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 91 of 253 |
Current Quarter EPS Est: | 4.93 |